

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**康臣藥業集團有限公司**  
**CONSUN PHARMACEUTICAL GROUP LIMITED**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1681)**

## **DISCLOSEABLE TRANSACTIONS SUBSCRIPTIONS FOR WEALTH MANAGEMENT PRODUCTS**

### **SUBSCRIPTIONS OF WEALTH MANAGEMENT PRODUCTS**

The Board announces that on 1 August 2025, the Company's subsidiary, Horgos Consun, subscribed for a wealth management product from SPD Bank with a principal amount of RMB252,000,000. On 4 August 2025, the Company's subsidiaries, Horgos Consun, Yulin Pharmaceutical and Inner Mongolia Consun, subscribed for certain wealth management products from SPDB Wealth Management (a wholly-owned subsidiary of SPD Bank) with an aggregate principal amount of RMB623,500,000. The Group utilised its idle funds for the payment of the Subscriptions.

### **LISTING RULES IMPLICATIONS**

Subscription A, on a standalone basis, does not constitute a discloseable transaction of the Company under Chapter 14 of the Listing Rules, however, as all the wealth management products were subscribed from SPD Bank or SPDB Wealth Management, similar in nature and within 12 months, the Subscriptions shall be aggregated in accordance with Rules 14.22 and 14.23 of the Listing Rules.

As one or more applicable percentage ratios calculated (on an aggregated basis) pursuant to Rule 14.07 of the Listing Rules for the Subscriptions exceed 5% but are all less than 25%, the Subscriptions constitute discloseable transactions of the Company under Chapter 14 of the Listing Rules, and are subject to the reporting and announcement requirements, but exempt from the shareholders' approval requirement under Chapter 14 of the Listing Rules.

### **SUBSCRIPTIONS OF WEALTH MANAGEMENT PRODUCTS**

The Board announces that on 1 August 2025, the Company's subsidiary, Horgos Consun, subscribed for a wealth management product from SPD Bank with a principal amount of RMB252,000,000. On 4 August 2025, the Company's subsidiaries, Horgos Consun, Yulin Pharmaceutical and Inner Mongolia Consun, subscribed for certain wealth management products from SPDB Wealth Management (a wholly-owned subsidiary of SPD Bank) with an aggregate principal amount of RMB623,500,000. The Group utilised its idle funds for the payment of the Subscriptions.

A summary of the principal terms of each of the Subscriptions are set out as follows:

## Subscription A

<b>Date of subscription:</b>	1 August 2025
<b>Parties:</b>	(i) Horgos Consun (as subscriber) (ii) SPD Bank (as manager) (iii) SPD Bank (as custodian)
<b>Name of product:</b>	Liduoduo Company's Stable Profit 25JG3323 (Monthly Compound Interest Undertaking Payment B) RMB Corporate Structured Deposit* (利多多公司穩利25JG3323期(月月滾利承接款 B)人民幣對公結構性存款)
<b>Type of product:</b>	Principal-guaranteed with floating return
<b>Risk level of product (internal risk rating by SPD Bank):</b>	Low risk
<b>Principal amount of the subscription:</b>	RMB252,000,000
<b>Term of product:</b>	25 days, from 4 August 2025 to 29 August 2025
<b>Expected annualised return rate:</b>	from 0.7% to 2.0% per annum

## Subscriptions B

	Subscription B1	Subscription B2	Subscription B3
<b>Date of subscription:</b>	4 August 2025		
<b>Parties:</b>	(i) Horgos Consun (as subscriber) (ii) SPDB Wealth Management (as manager) (iii) SPD Bank (as custodian)	(i) Yulin Pharmaceutical (as subscriber)	(i) Inner Mongolia Consun (as subscriber)
<b>Name of product:</b>	SPDB Wealth Management Tiantianli Cash Treasure No. 39* (浦銀理財天添利現金寶 39 號)		
<b>Type of product:</b>	Fixed Return		
<b>Risk level of product (internal risk rating by SPDB Wealth Management):</b>	Low risk (R1)		
<b>Principal amount of the subscription:</b>	RMB300,000,000	RMB100,000,000	RMB20,000,000
<b>Term of product:</b>	Subject to the redemption time of the subscriber		
<b>Expected annualised return rate:</b>	The performance will fluctuate with the market and is subject to uncertainty		

## Subscriptions C

	Subscription C1	Subscription C2	Subscription C3
<b>Date of subscription:</b>	4 August 2025		
<b>Parties:</b>	(i) Horgos Consun (as subscriber)	(i) Yulin Pharmaceutical (as subscriber)	(i) Inner Mongolia Consun (as subscriber)
	(ii) SPDB Wealth Management (as manager)		
	(iii) SPD Bank (as custodian)		
<b>Name of product:</b>	SPDB Wealth Management Tiantianying Zengli No. 25 Cash Management Product* (浦銀理財天添盈增利 25 號現金管理產品)		
<b>Type of product:</b>	Fixed Return		
<b>Risk level of product (internal risk rating by SPDB Wealth Management):</b>	Low risk (R1)		
<b>Principal amount of the subscription:</b>	RMB80,000,000	RMB103,500,000	RMB20,000,000
<b>Term of product:</b>	Subject to the redemption time of the subscriber		
<b>Expected annualised return rate:</b>	The performance will fluctuate with the market and is subject to uncertainty		

## REASONS FOR AND BENEFITS OF THE SUBSCRIPTIONS

The Directors are of the view that (i) the Subscriptions provide the Group with better return than fixed deposits generally offered by commercial banks in the PRC; (ii) the Subscriptions were funded by the Group's surplus cash reserves, and thus would not affect the Group's working capital position or operation; and (iii) appropriate wealth management with low risk exposure is conducive to enhancing the utilisation of capital and increasing income from idle funds of the Group. Accordingly, the Directors consider that the Subscriptions are on normal commercial terms which are fair and reasonable and in the interests of the Company and the Shareholders as a whole.

## INFORMATION ON THE PARTIES

### The Group

The Group is principally engaged in the manufacture and sale of pharmaceuticals and research and development of pharmaceutical products. The pharmaceutical products of the Company include kidney medicines, contrast medium and others. The Group has two reportable segments, (i) Consun pharmaceutical segment which manufactures and sells modern Chinese medicines and medical contrast medium; and (ii) Yulin pharmaceutical segment which manufactures and sells traditional Chinese medicines.

### Horgos Consun and Inner Mongolia Consun

Each of Horgos Consun and Inner Mongolia Consun is an indirect wholly-owned subsidiary of the Company established in the PRC and principally engaged in the production and sales of pharmaceutical products.

## **Yulin Pharmaceutical**

Yulin Pharmaceutical is an indirect non-wholly owned subsidiary of the Company established in the PRC and principally engaged in production and sales of pharmaceutical products.

## **SPDB Wealth Management**

SPDB Wealth Management is a company incorporated in the PRC with limited liability and is a wholly-owned subsidiary of SPD Bank. It is principally engaged in public issuance of wealth management products to the general public, non-public issuance of wealth management products to qualified investors, management of the entrusted investments and properties, provision of consultancy and advisory services on wealth management; and other businesses approved by banking supervisory authorities of the State Council.

## **SPD Bank**

SPD Bank is a licensed bank incorporated under the laws of the PRC and listed on the Shanghai Stock Exchange (stock code: 600000). The principal businesses of SPD Bank include finance and trust investment business.

To the best of the Directors' knowledge, information and belief having made all reasonable enquiry, SPD Bank and SPDB Wealth Management and their ultimate beneficial owner(s) are third parties independent from each of the Company and its connected persons.

## **LISTING RULES IMPLICATIONS**

Subscription A, on a standalone basis, does not constitute a discloseable transaction of the Company under Chapter 14 of the Listing Rules, however, as all the wealth management products were subscribed from SPD Bank or SPDB Wealth Management, similar in nature and within 12 months, the Subscriptions shall be aggregated in accordance with Rules 14.22 and 14.23 of the Listing Rules.

As one or more applicable percentage ratios calculated (on an aggregated basis) pursuant to Rule 14.07 of the Listing Rules for the Subscriptions exceed 5% but are all less than 25%, the Subscriptions constitute discloseable transactions of the Company under Chapter 14 of the Listing Rules, and are subject to the reporting and announcement requirements, but exempt from the shareholders' approval requirement under Chapter 14 of the Listing Rules.

## DEFINITIONS

In this announcement, the following expressions shall, unless the context requires otherwise, have the following meanings:

“Board”	the board of Directors
“Company”	Consun Pharmaceutical Group Limited, an exempted company incorporated in Cayman Islands with limited liability and the issued Shares of which are listed on the main board of the Stock Exchange (stock code: 1681)
“connected person(s)”	shall have the meaning ascribed to it in the Listing Rules
“Director(s)”	director(s) of the Company
“Group”	the Company and its subsidiaries
“Hong Kong”	Hong Kong Special Administrative Region of the PRC
“Horgos Consun”	Consun Pharmaceutical (Horgos) Co., Ltd.* (康臣藥業(霍爾果斯)有限公司), an indirect wholly-owned subsidiary of the Company established in the PRC
“Inner Mongolia Consun”	Consun Pharmaceutical (Inner Mongolia) Co., Ltd (康臣藥業(內蒙古)有限責任公司)*, an indirect wholly-owned subsidiary of the Company established in the PRC
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“PRC”	the People’s Republic of China except where the context requires, references in this announcement to the PRC or Mainland China excluding Hong Kong, China; Macau, China; and Taiwan, China
“RMB”	Renminbi, the lawful currency of the PRC
“Share(s)”	ordinary share(s) with par value of HK\$0.10 each in the share capital of the Company
“Shareholder(s)”	the holder(s) of Share(s)
“SPD Bank”	Shanghai Pudong Development Bank Co., Ltd.* (上海浦東發展銀行股份有限公司), a licensed bank incorporated under the laws of the PRC and listed on The Shanghai Stock Exchange (stock code: 600000)

“SPDB Wealth Management”	SPD Wealth Management Co., Ltd.* (浦銀理財有限責任公司), a company incorporated under the laws of the PRC with limited liability
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Subscription A”	the subscription by Horgos Consun for Liduoduo Company’s Stable Profit 25JG3323 (Monthly Compound Interest Undertaking Payment B) RMB Corporate Structured Deposit* (利多多公司穩利 25JG3323 期(月月滾利承接款B)人民幣對公結構性存款) for the principal amount of RMB252,000,000
“Subscriptions B”	Collectively, Subscription B1, Subscription B2 and Subscription B3, in relation to SPDB Wealth Management Tiantianli Cash Treasure No. 39* (浦銀理財天添利現金寶39號)
“Subscription B1”	the subscription by Horgos Consun for SPDB Wealth Management Tiantianli Cash Treasure No. 39* (浦銀理財天添利現金寶39號) for the principal amount of RMB300,000,000
“Subscription B2”	the subscription by Yulin Pharmaceutical for SPDB Wealth Management Tiantianli Cash Treasure No. 39* (浦銀理財天添利現金寶39號) for the principal amount of RMB100,000,000
“Subscription B3”	the subscription by Inner Mongolia Consun for SPDB Wealth Management Tiantianli Cash Treasure No. 39* (浦銀理財天添利現金寶39號) for the principal amount of RMB20,000,000
“Subscriptions C”	Collectively, Subscription C1, Subscription C2 and Subscription C3, in relation to SPDB Wealth Management Tiantianying Zengli No. 25 Cash Management Product* (浦銀理財天添盈增利25號現金管理產品)
“Subscription C1”	the subscription by Horgos Consun for SPDB Wealth Management Tiantianying Zengli No. 25 Cash Management Product* (浦銀理財天添盈增利25號現金管理產品) for the principal amount of RMB80,000,000
“Subscription C2”	the subscription by Yulin Pharmaceutical for SPDB Wealth Management Tiantianying Zengli No. 25 Cash Management Product* (浦銀理財天添盈增利25號現金管理產品) for the principal amount of RMB103,500,000
“Subscription C3”	the subscription by Inner Mongolia Consun for SPDB Wealth Management Tiantianying Zengli No. 25 Cash Management Product* (浦銀理財天添盈增利25號現金管理產品) for the principal amount of RMB20,000,000

“Subscriptions”	collectively, Subscription A, Subscriptions B and Subscriptions C
“subsidiary(ies)”	shall have the meaning ascribed to it in the Listing Rules
“Yulin Pharmaceutical”	Guangxi Yulin Pharmaceutical Group Co., Ltd.* (廣西玉林製藥集團有限責任公司), an indirect subsidiary of the Company established in the PRC
“%”	per cent.

By order of the Board  
**Consun Pharmaceutical Group Limited**  
**AN Meng**  
*Chairman*

Hong Kong, 4 August 2025

*As at the date of this announcement, the Board comprises Mr. An Meng, Professor Zhu Quan and Mr. Young Yuk Chuen David as executive Directors; Dr. Zhang Lihua as non-executive Director; Mr. Feng Zhongshi, Professor Li Yikai, Mr. Li Zhuoguang and Mr. Duan Weiwu as independent non-executive Directors.*